



# CALL TO ACTION:

## CONGRESS MUST FUND THE LUNG CANCER RESEARCH PROGRAM AT \$60M (FY 2026)

**The Lung Cancer Research Program (LCRP)** is within the Congressionally Directed Medical Research Programs (CDMRP) administered by the Department of Defense (DOD). The mission of the LCRP is to support and integrate research from multiple disciplines for risk assessment, prevention, early detection, diagnosis, management and treatment for the control and cure of lung cancer.

### PROGRAM PRIORITIES:

- Foster exploratory and translational research to understand and treat lung cancer
- Facilitate early, pilot clinical trials
- Enhance research capacity

### PROGRAM IMPACT:

- The LCRP supports research investigating potential therapeutic strategies, as well as tools and technologies for detection and screening.
- The LCRP introduced the Patient-Centered Outcomes and Survivorship Award in FY23 to address the needs of lung cancer survivors, including managing side effects, improving quality of life and preventing disease recurrences.

### WHY IS THERE A NEED FOR LUNG CANCER RESEARCH?



#### Lung Cancer in the U.S.

Leading cause of cancer mortality, accounting for **20%** of all deaths

Over **226,650** men and women diagnosed each year

Over **124,730** will die each year



**20%**

of all lung cancers occur in people with no smoking history



#### 900,000 VETERANS

are at risk for lung cancer due to age, smoking and other environmental exposure during and after military service




#### 15 VETERANS

die each day from lung cancer


**The LCRP supports research that is relevant to the healthcare needs of military service members, veterans and their families**

More than **26,000** individuals have outpatient treatments or hospitalizations within the Military Health System (MHS) due to lung cancer.

There were over **45,000** bed days and more than **270,000** outpatient encounters for lung cancer per year within the MHS.



## FUNDING HISTORY




Source: <https://cdmp.army.mil/lcrp/>

## HOW IS THE PROGRAM ADVANCING LUNG CANCER RESEARCH?

The LCRP directed FY22 investments into six program priorities:

- **Treatment** - \$10,223,802
- **Molecular Mechanisms of Initiation and Progression** - \$2,429,933
- **Prevention of Recurrence or Metastases** - \$1,992,315
- **Mechanisms of Resistance to Treatment** - \$1,536,473
- **Screening and Early Detection** - \$1,273,063
- **Non-Tobacco Contributors to Lung Cancer Development** - \$536,027



**Congress must answer the call to action for lung cancer, the leading cause of cancer deaths in the U.S.**

**FUND LCRP at \$60M in FY2026**

Cancer Stat Facts: Common Cancer Sites. 2023. | Odani S, Agaku IT, et al. 2018. Tobacco Product Use Among Military Veterans—United States, 2010–2015. Morbidity and Mortality Weekly Report 67:7–12. | Moghanaki D and Hagan, M. 2020. Strategic Initiatives for Veterans with Lung Cancer. Federal Practitioner 37(Suppl 4): S76–S80. <https://doi.org/10.12788/fp.0019>. | Centers for Disease Control and Prevention. 2023. Lung Cancer Statistics. <https://www.cdc.gov/cancer/lung/statistics/index.htm>. | Lung Cancer Among People Who Never Smoked. 2023.